Gel buffer solution and method used for capillary electrophoresis

By using specific formula gel buffers in capillary electrophoresis, including dextran, Tris, boric acid, glycerol, SDS and EDTA, the problem of the inability of the prior art to effectively detect impurities with small differences in molecular size in protein drugs is significantly Improved resolution and monitoring accuracy.

WO2024235226A1PCT designated stage expired Publication Date: 2024-11-21BIO THERA SOLUTIONS LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093121
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-14
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing commercial reagents and platform-based methods cannot effectively detect impurities with small differences in molecular size in protein drugs, resulting in difficulty in capillary electrophoresis separation and detection, affecting drug quality control.

Method used

Provided is a gel buffer for capillary electrophoresis, comprising a combination of hydrophilic polymers such as dextran, buffering components such as Tris and boric acid, organic additives such as glycerol, detergents such as SDS and metal chelating agents such as EDTA , used to improve the resolution of the main peak and acromion. Specific formulations of this buffer include 500mM-900mM Tris, 500mM-900mM boric acid, 12%-20% w/v dextran, 5%-15% v/v glycerol, 0.1%-2% w/v SDS and 2mM -15mM EDTA, used for capillary electrophoresis to separate protein samples.

Benefits of technology

The resolution of the main peak and acromum is significantly improved, and the acromum impurities with small differences in molecular weight from the main peak are effectively separated and monitored, which improves the accuracy and reliability of drug quality analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093121_21112024_PF_FP_ABST
    Figure CN2024093121_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A method and a gel buffer solution used for protein separation by capillary electrophoresis (CE). The gel buffer solution comprises a buffer component, a hydrophilic polymer, an organic additive, a detergent and a metal chelating agent. Using the gel buffer solution can improve the separation degree of main peaks and shoulder peaks for protein separation by capillary electrophoresis (CE).
Need to check novelty before this filing date? Find Prior Art

Description

Gel buffers and methods for capillary electrophoresis Technical Field

[0001] The present invention relates to a method and a gel buffer for separating proteins by capillary electrophoresis (CE). Background Art

[0002] Capillary electrophoresis (CE) is an analytical method that uses a high-voltage direct current electric field as the driving force and a capillary as the separation channel. The commonly used sodium dodecyl sulfate-capillary electrophoresis (CE-SDS) is a gel-free sieving electrophoresis that separates proteins using a molecular sieve formed by a polymer solution within the capillary tube. During sample preparation, the protein sample and SDS are heated simultaneously. SDS and the protein bind proportionally to form a negatively charged complex with a linear conformation. Regardless of protein type, they exhibit a consistent charge-to-mass ratio, and their mobility depends on their size. Samples are separated by different migration speeds within the capillary according to their molecular weight. Therefore, CE-SDS capillary electrophoresis has become an important method for analyzing molecular size isomers of various recombinant proteins such as monoclonal antibodies, bispecific antibodies, and fusion proteins, as well as biological products such as antibody-drug conjugates (ADCs). Currently, the industry has developed commercial reagents for this method and has established a platform for the routine analysis of various proteins.

[0003] The numerous impurities of smaller molecular sizes in protein pharmaceuticals present significant challenges in their separation and detection. Current commercial reagents and platform-based methods are still unable to effectively detect these impurities. Furthermore, regulatory authorities are increasingly aware of the challenges this technical bottleneck poses to drug quality control. Therefore, research to improve the resolution of CE-SDS methods is of great significance for drug quality analysis.

[0004] Summary of the Invention

[0005] In one aspect, the present invention provides a gel buffer for use in capillary electrophoresis separation of a target protein in a sample. In some embodiments, the present invention provides a gel buffer for improving the resolution of a main peak and shoulder peaks when separating a protein sample by capillary electrophoresis.

[0006] In some embodiments, the gel buffer comprises one or more selected from the group consisting of a buffer component, a hydrophilic polymer, an organic additive, a detergent, a metal chelator, and any combination thereof.

[0007] In some embodiments, the gel buffer comprises a hydrophilic polymer. In some embodiments, the hydrophilic polymer is dextran, polyacrylamide, a cellulose derivative, and polyethylene oxide. In some embodiments, the hydrophilic polymer is dextran (MW ~ 2000kDa). In some embodiments, the dextran concentration is 11%-20%. In some embodiments, the dextran concentration is 13%-17%. In some embodiments, the dextran concentration is 15%.

[0008] In some embodiments, the buffer component comprises Tris (trishydroxymethylaminomethane), boric acid, phosphate, citrate, succinate, and acetic acid, or any combination thereof. In some embodiments, the buffer component comprises Tris. In some embodiments, the buffer component comprises Tris and boric acid. In some embodiments, the buffer component comprises about 500 mM to about 1000 mM Tris and about 500 mM to about 900 mM boric acid. In some embodiments, the buffer component comprises about 500 mM to about 1000 mM, about 600 mM to about 900 mM, about 650 mM to about 900 mM, about 700 mM to about 900 mM, about 750 mM to about 900 mM, about 800 mM to about 900 mM, or about 850 mM to about 900 mM Tris and about 500 mM to about 900 mM, about 600 mM to about 900 mM, about 650 mM to about 900 mM, about 700 mM to about 900 mM, about 750 mM to about 900 mM, about 800 mM to about 900 mM, or about 850 mM to about 900 mM boric acid. In some embodiments, the buffer component comprises about 700 mM to about 900 mM Tris and about 650 mM to about 900 mM boric acid. In some embodiments, the buffer component comprises about 600 mM Tris and about 600 mM boric acid. In some embodiments, the buffer component comprises about 850 mM Tris and about 700 mM boric acid.

[0009] In some embodiments, the pH of the buffer is about 8.0-9.0. In some embodiments, the pH of the buffer is about 8.0. In some embodiments, the pH of the buffer is about 8.5.

[0010] In some embodiments, the organic additive is an alcohol, such as mannitol, glycerol, ethylene glycol, ethanol, methanol, or any combination thereof. In some embodiments, the concentration of the organic additive is about 0.1% to about 30% v / v. In some embodiments, the organic additive is about 5% to about 15% v / v glycerol. In some embodiments, the organic additive is about 10% v / v glycerol.

[0011] In some embodiments, the detergent is a hydrophobic detergent. In some embodiments, the hydrophobic detergent is selected from sodium dodecyl sulfate (SDS), sodium tridecyl sulfate, sodium tetradecyl sulfate (STS), sodium pentadecyl sulfate, sodium hexadecyl sulfate (SHS), sodium heptadecanyl sulfate, and sodium octadecyl sulfate (SOS). In some embodiments, the detergent is present in an amount of about 0.1% to about 2% w / v. In some embodiments, the detergent is present in an amount of about 0.2% to about 2% w / v. In some embodiments, the detergent is present in an amount of about 0.5% to about 2% w / v.

[0012] In some embodiments, the metal chelator is ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DPTA) or any combination thereof. In some embodiments, the content of the metal chelator is about 2mM to about 15mM. In some embodiments, the content of the metal chelator is about 5mM to about 15mM.

[0013] In some embodiments, the gel buffer comprises Tris, boric acid, dextran, glycerol, SDS, and EDTA.

[0014] In some embodiments, the gel buffer comprises about 500 mM to about 900 mM Tris, about 500 mM to about 900 mM boric acid, about 12% to about 20% w / v dextran, about 5% to about 15% v / v glycerol, about 0.1% to about 2% w / v SDS, and about 2 mM to about 15 mM EDTA.

[0015] In some embodiments, the gel buffer comprises about 600 mM to about 900 mM Tris, about 600 mM to about 900 mM boric acid, about 13% to about 20% w / v dextran, about 5% to about 15% v / v glycerol, about 0.2% to about 2% w / v SDS, and about 5 mM to about 15 mM EDTA.

[0016] In some embodiments, the gel buffer comprises about 600 mM to about 900 mM Tris, about 600 mM to about 900 mM boric acid, about 13% to about 20% w / v dextran, about 5% to about 15% v / v glycerol, about 0.5% to about 2% w / v SDS, and about 5 mM to about 15 mM EDTA.

[0017] In some embodiments, the gel buffer comprises about 600 mM Tris, about 600 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS, and about 5 mM EDTA.

[0018] In some embodiments, the gel buffer comprises about 850 mM Tris, about 700 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS, and about 5 mM EDTA.

[0019] On the other hand, the present invention provides a method for separating protein samples by capillary electrophoresis, comprising first adding the gel buffer provided by the present invention into a capillary, injecting the protein sample, separating, and detecting.

[0020] In some embodiments, the methods of the present invention comprise the following steps:

[0021] (1) Prepare protein samples;

[0022] (2) preparing the above-mentioned gel buffer solution;

[0023] (3) Capillary electrophoresis experiment: first add gel buffer into the capillary, inject the protein sample, separate and detect.

[0024] In some embodiments, gel buffer preparation comprises mixing the components with water.

[0025] In some embodiments, preparing the protein sample comprises mixing the protein sample, a sample buffer, and an alkylating agent.

[0026] In some embodiments, the sample buffer comprises Na2HPO4, citric acid, SDS, and water. In some embodiments, the sample buffer comprises 40 mM Na2HPO4-citric acid buffer solution and 1% w / v SDS, with a pH of 6.5.

[0027] In some embodiments, the alkylating agent is iodoacetamide.

[0028] In some embodiments, preparing a protein sample comprises mixing 25 μL of a 1-4 mg / mL protein sample, 70 μL of a sample buffer, and 5 μL of 0.25 M iodoacetamide; wherein the sample buffer is 40 mM Na2HPO4-citric acid buffer solution and 1% w / v SDS, with a pH of 6.5.

[0029] In some embodiments, step (1) comprises denaturing the protein in a sample buffer.

[0030] In some embodiments, denaturation is carried out at a temperature of at least about 60°C, at least about 65°C, at least about 70°C, at least about 75°C, or at least about 80°C. In some embodiments, denaturation is carried out at a temperature of about 60°C to about 70°C, about 65°C to about 70°C, or about 60°C to about 65°C. In some embodiments, denaturation is carried out for at least about 3 minutes, at least about 4 minutes, at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9 minutes, or at least about 10 minutes. In some embodiments, the denaturation is carried out at a temperature of about 65°C for 5 minutes.

[0031] In some embodiments, the concentration of the protein sample in step (1) is about 0.25 mg / mL to about 1 mg / mL. In some embodiments, the concentration of the protein sample in step (1) is about 1 mg / mL.

[0032] In some embodiments, the inner diameter of the capillary is about 25 μm to 100 μm. In some embodiments, the inner diameter of the capillary is about 50 μm.

[0033] In some embodiments, in step (3), the capillary electrophoresis experiment uses a non-coated quartz capillary with an effective capillary length of 23 cm to 32 cm, such as 24.5 cm and 28.5 cm, and an inner diameter of 50 μm.

[0034] In some embodiments, in step (3), the separation voltage during the capillary electrophoresis experiment is 10 kV-17 kV, such as 16.5 kV, 14 kV, 12 kV or 10 kV.

[0035] In some embodiments, in step (3), a diode array detector (DAD detector) is used for detection, and the detection wavelength is 220 nm.

[0036] In some embodiments, in step (3), the capillary electrophoresis experiment uses a non-coated quartz capillary with an effective capillary length of 28.5 cm and an inner diameter of 50 μm, and the separation voltage during the capillary electrophoresis experiment is 10 kV.

[0037] In some embodiments, the protein is an antibody. In some embodiments, the antibody is an isotype selected from IgM, IgA, IgE, IgD, and IgG. In some embodiments, the IgG antibody is selected from IgG1, IgG2, IgG3, and IgG4. In some embodiments, the protein includes an enzyme, a hormone, a cytokine, a cell surface receptor, a protease, a cytokine receptor, an antibody (e.g., a monoclonal antibody, a bispecific antibody, a multispecific antibody, only a heavy chain antibody, or a nanobody), an antibody-drug conjugate (ADC), or any combination thereof. In some embodiments, the protein is a fusion protein. In some embodiments, the fusion protein is fused to a heterologous portion. In some embodiments, the heterologous portion is a portion that extends half-life. In some embodiments, the portion that extends half-life comprises Fc. In some embodiments, the antibody is a monoclonal antibody, a bispecific antibody, a multispecific antibody, only a heavy chain antibody, or a nanobody. In some embodiments, the protein is bevacizumab. In some embodiments, the protein is a bispecific antibody against TIGIT and CTLA-4.

[0038] In some embodiments, the molecular weight of the protein is in the range of 10-250 kDa. In some embodiments, the molecular weight of the protein analyzed by the methods of the present invention is about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 50 kDa, about 60 kDa, about 70 kDa, about 75 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 160 kDa, about 170 kDa, about 175 kDa, about 180 kDa, about 190 kDa, about 200 kDa, about 210 kDa, about 220 kDa, about 230 kDa, about 240 kDa, or about 250 kDa.

[0039] In some embodiments, the gel buffer is for reducing CE-SDS. In some embodiments, the gel buffer is for non-reducing CE-SDS (nrCE-SDS).

[0040] The nrCE-SDS method of the present invention can significantly improve the resolution between the main peak and the shoulder peak, and effectively separate and monitor the shoulder peak impurities with a smaller molecular weight difference from the main peak. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] FIG1 shows nrCE-SDS detection spectra of mAb1 samples with different concentrations, where 1 mg / mL, 2 mg / mL, 3 mg / mL, and 4 mg / mL are the sample concentrations of mAb1.

[0042] Figure 2 shows the nrCE-SDS detection spectra of mAb1 samples at different capillary effective lengths, where 24.5 cm and 28.5 cm represent the capillary effective lengths, respectively.

[0043] Figure 3 shows the nrCE-SDS detection spectra of mAb1 samples at different separation voltages, where 16.5 kV, 14 kV, 12 kV, and 10 kV represent the separation voltages.

[0044] FIG4 shows nrCE-SDS detection spectra of mAb1 samples at different dextran concentrations, where 9%, 12%, and 15% represent dextran concentrations (w / v).

[0045] Figure 5 shows the nrCE-SDS comparison of mAb1-STD. The left side represents Method 1 (conventional method), the right side represents Method 2, HL represents an impurity containing one heavy chain and one light chain, HH represents an impurity containing two heavy chains, and HHL represents an impurity containing two heavy chains and one light chain.

[0046] Figure 6 shows the nrCE-SDS comparison of the mAb1 sample (mAb1-GW-14d) after high-temperature degradation. The left side represents Method 1 (standard method), and the right side represents Method 2. HL represents an impurity containing one heavy chain and one light chain, HH represents an impurity containing two heavy chains, and HHL represents an impurity containing two heavy chains and one light chain.

[0047] Figure 7 shows the nrCE-SDS comparison of bevacizumab mAb2 samples. The left side represents Method 1 (conventional method), and the right side represents Method 2. HL represents an impurity containing one heavy chain and one light chain, HH represents an impurity containing two heavy chains, and HHL represents an impurity containing two heavy chains and one light chain.

[0048] Figure 8 shows the nrCE-SDS comparison of bevacizumab mAb3 samples. The left side represents Method 1 (conventional method), the right side represents Method 2, HL represents an impurity containing one heavy chain and one light chain, HH represents an impurity containing two heavy chains, and HHL represents an impurity containing two heavy chains and one light chain.

[0049] Figure 9 shows the nrCE-SDS comparison of the bispecific antibody bsAb1 samples. The left side represents method 1 (conventional method), the right side represents method 2, HH represents an impurity containing two heavy chains, and HHL represents an impurity containing two heavy chains and one light chain. DETAILED DESCRIPTION

[0050] The following is a detailed description of the technical solution of the present invention, which does not limit the scope of protection of the present invention. Non-essential modifications and adjustments made by others based on the concept of the present invention still fall within the scope of protection of the present invention.

[0051] the term

[0052] Weight-to-volume (w / v) percentages, where weight can be expressed in grams and volume can be expressed in milliliters. For example, a solution containing 1% w / v SDS means that 1g of SDS is present in 100mL of solution, or the SDS content is 0.01g / mL.

[0053] "About" refers to the conventional error range of the corresponding numerical value that is readily known to those skilled in the relevant art. In some embodiments, "about" mentioned herein refers to the described numerical value and its ±10%, ±5%, ±1% or ±0.1% range.

[0054] The term "separation" refers to the separation of protein components in a sample (including one or more target proteins and one or more impurities) in order to determine the purity of the target proteins and the types and amounts of impurities in the sample. Separation can be performed via electrophoresis, in which an electric field is used to force negatively charged particles through a substance. When particles have the same uniform charge, they migrate through the electric field based on their size, and their different mobilities result in the separation of particles, including the target protein.

[0055] The term "buffer" refers to a solution that resists changes in pH through the action of its acid-base coupled components.

[0056] The term "sample buffer" refers to a buffer added to a protein sample to prepare it for running on a gel for electrophoretic analysis. Buffer solutions resist changes in pH through the action of their acid-base conjugate components. Sample buffers may contain detergents to denature proteins and render them negatively charged.

[0057] The term "gel buffer" refers to a hydrogel composition added to an electrophoresis apparatus (e.g., a capillary) for separating proteins. In some embodiments, the gel buffer comprises one or more additional components selected from a buffer component, an organic additive, a hydrophilic polymer, a metal chelator, and any combination thereof, and water (typically ultrapure water) to form a gel.

[0058] In some embodiments, the detergent is sodium dodecyl sulfate (SDS), which has been widely used in protein denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and capillary gel electrophoresis using sodium dodecyl sulfate (CE-SDS) techniques. This can be attributed to the generally recognized fact that proteins tend to bind to a relatively constant amount of SDS on a weight basis (~1.4 g SDS / 1 g protein), thereby producing a uniform mass-to-charge ratio of the SDS-protein complex in most cases. Therefore, the intrinsic polypeptide charge of the protein molecules becomes negligible, and the final separation depends entirely on the difference in the relative molecular weight of their denatured polypeptides.

[0059] In some embodiments, the detergent is a hydrophobic detergent. In some embodiments, the hydrophobic detergent can also be sodium tridecyl sulfate, sodium tetradecyl sulfate (STS), sodium pentadecyl sulfate, sodium hexadecyl sulfate (SHS), sodium heptadecanyl sulfate, and sodium octadecyl sulfate (SOS). In some embodiments, the concentration of the hydrophobic detergent in the sample buffer or gel is about 0.001% to about 4% w / v. In some embodiments, the concentration of the hydrophobic detergent can be about 0.001%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9% or about 3.0%.

[0060] In some embodiments, examples of buffer components include, but are not limited to, tris(hydroxymethyl)aminomethane (Tris), boric acid, phosphate, citrate, succinate, and acetic acid, or any combination thereof. In some embodiments, the buffer component comprises Tris. In some embodiments, the buffer component comprises Tris and boric acid. In some embodiments, the buffer component comprises about 500 mM to about 1000 mM Tris and about 500 mM to about 900 mM boric acid. In some embodiments, the buffer component comprises about 500 mM to about 1000 mM, about 600 mM to about 900 mM, about 650 mM to about 900 mM, about 700 mM to about 900 mM, about 750 mM to about 900 mM, about 800 mM to about 900 mM, or about 850 mM to about 900 mM Tris and about 500 mM to about 900 mM, about 600 mM to about 900 mM, about 650 mM to about 900 mM, about 700 mM to about 900 mM, about 750 mM to about 900 mM, about 800 mM to about 900 mM, or about 850 mM to about 900 mM boric acid. In some embodiments, the buffer component comprises about 600 mM to about 900 mM Tris and about 600 mM to about 700 mM boric acid. In some embodiments, the buffer component comprises about 600 mM Tris and about 600 mM boric acid. In some embodiments, the buffer component comprises about 850 mM Tris and about 700 mM boric acid.

[0061] In some embodiments, the organic additive includes mannitol, glycerol, ethylene glycol, ethanol, methanol, propylene glycol, monomethyl ether of diethylene glycol, dimethyl ether of diethylene glycol, methyl carbitol, tetrahydrofuran, dibutyl ether, dimethylformamide, sulfolane, or alcohols having 1-4 carbon atoms, or any combination thereof.

[0062] In some embodiments, the hydrophilic polymer comprises dextran, polyacrylamide, polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol or any combination thereof. In some embodiments, the hydrophilic polymer is dextran (MW~2000kDa). In some embodiments, the hydrophilic polymer is dextran T2000. In some embodiments, the dextran concentration is about 11%-about 20%. In some embodiments, the dextran concentration is about 13%-about 17%. In some embodiments, the dextran concentration is about 15%.

[0063] In some embodiments, the metal chelator comprises ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), ethylene glycoltetraacetic acid (EGTA), trisodium nitrilotriacetate, trisodium hydroxyethylethylenediamine acetate (trisodium HEDTA), pentasodium diethylenetriaminoacetate, or uramil disodium acetate, or any combination thereof. Metal chelators such as EDTA can be used to prepare the electrophoresis gel buffer of the present invention in a concentration range of about 5 mM to about 15 mM.

[0064] The term "impurity" is used in its broadest sense to cover any undesirable component or compound within a mixture. In cell cultures, cell lysates, or clarified bulk (e.g., clarified cell culture supernatant), impurities include, for example, host cell nucleic acids (e.g., DNA) and host cell proteins present in the cell culture medium. Host cell impurity proteins include, but are not limited to, proteins naturally or recombinantly produced by the host cell, as well as proteins related to or derived from the protein of interest (e.g., proteolytic fragments), and impurities related to other processes.

[0065] The term "abundance" refers to the amount of a substance, such as an impurity or a protein of interest.

[0066] As used herein, the term "protein" is used in its broadest sense and includes any protein (natural or recombinant) present in a mixture that needs to be purified. Such proteins include, but are not limited to, enzymes, hormones, growth factors, cytokines, immunoglobulins (e.g., antibodies), and / or any fusion proteins. In some embodiments, the antibodies include monoclonal antibodies, bispecific antibodies, multispecific antibodies, heavy chain-only antibodies, or nanobodies.

[0067] In some embodiments, the protein is an antibody. In some embodiments, the antibody is an isotype selected from IgM, IgA, IgE, IgD, and IgG. In some embodiments, the IgG is selected from IgG1, IgG2, IgG3, and IgG4.

[0068] In some embodiments, an alkylating agent is added to non-reducing and partially reducing CE-SDS conditions to prevent fragmentation of the antibody molecule caused by disulfide bond disruption. In some embodiments, the alkylating agent comprises iodoacetamide (IAM), N-ethylmaleimide (NEM), or chloroacetamide.

[0069] In some embodiments, IgG molecules are treated with a reducing agent (e.g., β-mercaptoethanol (BME)) under reducing conditions to cleave disulfide bonds, and protein fragments including light chain (LC), heavy chain (HC), and non-glycosylated heavy chain (NGHC) are separated by size and electrophoretic mobility.

[0070] In some embodiments, denaturation can be performed at a temperature of at least about 60° C., at least about 65° C., at least about 70° C., at least about 75° C., or at least about 80° C., e.g., from about 60° C. to about 70° C., from about 65° C. to about 70° C., or from about 60° C. to about 65° C. In some embodiments, denaturation is performed for at least about 3 minutes, at least about 4 minutes, at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9 minutes, or at least about 10 minutes.

[0071] Shoulder peak: A small inflection that does not form a peak shape appears on the peak of the elution curve or absorption curve. It is shaped like a shoulder, so it is called a shoulder peak. It is usually an impurity peak that is different from the main substance (main peak) but cannot be baseline separated due to the limitation of the method separation degree.

[0072] Shoulder peak "separation" or "resolution" is a quantitative measure of how well two eluting peaks can be distinguished in a chromatographic separation. It is defined as the difference in retention time between the two peaks divided by the sum of the widths of the eluting peaks, expressed as follows: R = 2(R t2 –R t1 ) / (W2+W1). Where R = resolution between two peaks, R t1 and R t2 are the retention / migration times of peaks 1 and 2, respectively, and W2+W1 is the sum of the peak widths at baseline, with a tangent line drawn at 50% of the peak height.

[0073] In the following examples, unless otherwise specified, the reagents and instruments used are conventional reagents and instruments in the field and can be obtained commercially; the methods used are conventional technical methods in the field, and those skilled in the art can undoubtedly implement the methods and obtain corresponding results based on the contents of the examples.

[0074] The protein samples used in the following examples are bevacizumab samples, for example, mAb1 (BAT1706, manufactured by Bio-Thera), mAb2, and mAb3 are commercially available bevacizumab samples from other manufacturers. bsAb1 is a bispecific antibody against TIGIT and CTLA4.

[0075] Example 1

[0076] Reagents: Glycerol (Cat. No. G5516), Tris base ( Base (catalog number: T1503), boric acid (catalog number: B6768), ethylenediaminetetraacetic acid (EDTA, catalog number: V900106), and iodoacetamide (IAM, catalog number: V900335) were purchased from Sigma; sodium dodecyl sulfate (SDS, catalog number: S108346) was purchased from Aladdin; dextran (Dextran T2000, catalog number: 551020009006, Mw ~ 2000 kDa) was purchased from Pharmacosmos. Commercial SDS-MW gel buffer was purchased from Beckman, catalog number: A30341.

[0077] Capillary electrophoresis: CE-SDS experiments were performed using an Agilent / CE7100 capillary electrophoresis instrument with a diode array detector (DAD) at a wavelength of 220 nm. The capillary (uncoated quartz capillary) had an inner diameter of 50 μm and an effective length selected from 24.5 cm and 28.5 cm. The capillary temperature was 25°C. Electrophoretic separation voltages were selected from 16.5 kV, 14 kV, 12 kV, and 10 kV.

[0078] The sample buffer is formulated as follows: 40 mM Na2HPO4-citric acid buffer solution + 1% w / v SDS, pH 6.5. After the protein is added to the sample buffer, it binds to the SDS, denatures, and forms a complex with a linear conformation.

[0079] Preparation of non-reduced protein samples: Dilute an appropriate amount of protein sample with ultrapure water to a desired concentration (typically 4 mg / mL). Take 25 μL of the diluent, add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide to create a test sample with a protein concentration of 1 mg / mL. Mix thoroughly, centrifuge the contents of the tube to the bottom, and incubate in a 65°C water bath for 5 minutes. Cool to room temperature, centrifuge the contents again to the bottom of the tube, mix thoroughly, and transfer to a sample vial for testing.

[0080] Prepare the gel buffer as follows: Mix Trizma base, boric acid, EDTA, SDS, glycerol, and ultrapure water, heat at 65°C to dissolve, and after complete dissolution and cooling to room temperature, add dextran and place in a cool place until the dextran is completely dissolved. The formula of the gel buffer is shown in Table 1:

[0081] Table 1 Gel buffer formula

[0082] Example 2: Effect of sample concentration on method resolution

[0083] The CE-SDS method primarily uses electrokinetic injection. Both the ionic strength of the solution and the sample concentration (sample concentration refers to the concentration of protein in the sample) affect the injection volume. A typical sample concentration is 4 mg / mL, and the test protein concentration is 1 mg / mL. This example examines the effect of injection volume on the resolution of the method by varying the sample concentration.

[0084] Preparation of non-reduced protein test solution: Dilute the appropriate amount of mAb1 protein sample to 1, 2, 3, or 4 mg / mL with ultrapure water. Take 25 μL of the dilution, add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide, mix thoroughly, centrifuge the contents to the bottom of the tube, and incubate at 65°C for 5 minutes to obtain test solutions with protein concentrations of 0.25, 0.5, 0.75, and 1 mg / mL, respectively. After the test solution cools to room temperature, centrifuge the contents again to the bottom of the tube, mix thoroughly, and transfer to a sample vial for testing. Samples of varying concentrations were tested under the same capillary electrophoresis conditions. The test parameters are shown in the table below.

[0085] Table 2 Some parameter settings of the detection method

[0086] The results are shown in Table 3 and Figure 1. In the detection spectrum shown in Figure 1, a shoulder peak is clearly visible to the left of the main peak. At a conventional sample concentration (4 mg / mL), the resolution of this shoulder peak is only 0.34 (Table 3). As the sample concentration decreases, the resolution between the main peak and the shoulder peak gradually increases, reaching 0.82 at a sample concentration of 1 mg / mL (i.e., a test sample concentration of 0.25 mg / mL).

[0087] As the resolution increases, the amount of shoulder peak detected also increases. Furthermore, a decrease in sample concentration will inevitably lead to a decrease in the sensitivity of the detection method for low-abundance components in the sample. Therefore, to ensure that low-abundance components in the sample can also be accurately quantified, the sample protein concentration is maintained unchanged.

[0088] Table 3 nrCE-SDS detection results of samples with different concentrations

[0089] Example 3: Effect of capillary effective length on method resolution

[0090] The denaturant SDS unwinds the higher-order structure of proteins into a linear conformation and imparts negative charges at a fixed ratio. Therefore, the speed at which proteins move within the capillary depends on their molecular weight. Theoretically, when the relative speeds of molecules of different sizes in an electric field are constant, increasing their distance can improve the resolution of the method by increasing their distance.

[0091] Non-reduced protein sample preparation: Dilute the appropriate amount of mAb1 protein sample to 4 mg / mL with ultrapure water. Take 25 μL of the dilution and add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide, resulting in a test sample concentration of 1 mg / mL. After mixing, centrifuge the contents of the tube to the bottom and incubate in a 65°C water bath for 5 minutes. After cooling to room temperature, centrifuge the contents again to the bottom of the tube, mix thoroughly, and transfer to a sample vial for analysis. The capillary effective lengths were 24.5 cm and 28.5 cm, respectively. Other assay conditions remained the same. The assay parameters are shown in Table 4.

[0092] Table 4 Some parameter settings of the detection method

[0093] The results are shown in Figure 2 and Table 5. The experimental results show that the separation degree is improved from 0.34 to 0.45.

[0094] Table 5 nrCE-SDS detection results of different capillary effective lengths

[0095] Example 4: Effect of separation voltage on method resolution

[0096] By varying the electric field to increase the relative velocity difference between molecules, the separation between them can be improved. The effect of electric field variation on the separation resolution can be investigated by varying the separation voltage.

[0097] Non-reduced protein sample preparation: Dilute an appropriate amount of protein sample mAb1 to 4 mg / mL with ultrapure water. Take 25 μL of the dilution and add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide, resulting in a test sample concentration of 1 mg / mL. Mix thoroughly, centrifuge the contents of the tube to the bottom, and incubate at 65°C in a water bath for 5 minutes. After cooling to room temperature, centrifuge the contents again to the bottom of the tube, mix thoroughly, and transfer to a sample vial for analysis. Capillary electrophoresis separation voltages were set to 16.5 kV, 14 kV, 12 kV, and 10 kV, respectively. Other detection conditions remained the same. The detection method parameters are shown in Table 6.

[0098] Table 6 Some parameter settings of the detection method

[0099] The results are shown in Figure 3 and Table 7. The experimental results show that when the separation voltage is reduced from 16.5 kV to 10 kV, the resolution improves to a certain extent, but the improvement is limited. In addition, the separation time also increases due to the decrease in protein mobility caused by the reduction in separation voltage.

[0100] Table 7 nrCE-SDS detection results at different separation voltages

[0101] Example 5: Effect of Dextran Concentration in Gel Buffer on Method Resolution

[0102] Non-reduced protein sample preparation: Dilute an appropriate amount of protein sample mAb1 to 4 mg / mL with ultrapure water. Take 25 μL of the dilution and add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide, resulting in a test sample concentration of 1 mg / mL. After mixing, centrifuge the contents of the tube to the bottom and incubate in a 65°C water bath for 5 minutes. After cooling to room temperature, centrifuge the contents again to the bottom of the tube, mix thoroughly, and transfer to a sample vial for testing. Testing was performed using different gel buffer formulations, with all other test conditions remaining the same. The dextran concentrations in gel buffer formulations A, B, and C were 9%, 12%, and 15%, respectively. The test method parameters for this assay are shown in the table below.

[0103] Table 8 Detection method parameter settings

[0104] The experimental results are shown in FIG4 and Table 9. The results show that when the concentration of dextran in the gel buffer increases from 9% to 15%, the resolution is significantly improved. The resolution of formulation C is 1.5 times that of formulation A.

[0105] Table 9 nrCE-SDS detection results of gel buffer with different dextran concentrations

[0106] Example 6: Comparison of test results between method 2 and conventional method (method 1)

[0107] Preparation of non-reduced protein samples: Dilute appropriate amounts of protein samples (mAb1, mAb1-GW-14d (mAb1 after forced degradation at high temperature), mAb2, mAb3, and bsAb1) to 4 mg / mL with ultrapure water. Take 25 μL of the dilution, add 70 μL of sample buffer and 5 μL of 0.25 M iodoacetamide to obtain a protein concentration of 1 mg / mL.

[0108] After the test sample is mixed, the liquid in the tube is centrifuged to the bottom and then placed in a 65°C water bath for 5 minutes. After cooling to room temperature, the liquid is centrifuged again to the bottom of the tube, mixed thoroughly, and transferred to a sample bottle for testing. The samples were tested using Method 1 and Method 2, respectively. The test method parameters are shown in the table below.

[0109] Table 10 Detection method parameter settings

[0110] Method 2 was used alongside the existing standard method 1 to analyze different samples to compare the differences in resolution between the methods. The results are shown in Figures 5-9 and Table 11. For the mAb1 standard (mAb1-STD), which has very low impurity content, Method 1 was unable to resolve the shoulder peak, while Method 2 clearly resolved the shoulder peak with a resolution of 0.66. Furthermore, for the mAb1 high-temperature treated sample (mAb1-GW-14d), Method 2 doubled the resolution. For mAb2 and mAb3, Method 2 achieved resolution exceeding 2.8 times that of the original method. For the bispecific antibody bsAb1, which has a high impurity content, Method 2 achieved resolution 3.8 times that of Method 1.

[0111] The method presented here effectively improves the resolution of CE-SDS detection, maintaining a stable resolution of approximately 0.7 between the main peak and the shoulder peak across a wide range of samples. This method significantly improves the resolution between the main peak and impurities, effectively separating and monitoring shoulder peak impurities with a relatively small molecular weight difference from the main peak. The gel buffer described here makes the detection method more robust, reproducible, and stable.

[0112] Table 11 Comparison of separation of samples in different detection methods

Claims

1. A gel buffer comprising: a buffer component, a hydrophilic polymer, an organic additive, a detergent, and a metal chelating agent.

2. The gel buffer according to claim 1, wherein the hydrophilic polymer is selected from dextran, polyacrylamide, cellulose derivatives and polyethylene oxide; preferably, the hydrophilic polymer is dextran with a molecular weight of about 2000 kDa; preferably, the concentration of the dextran is about 11%-about 20% w / v.

3. The gel buffer according to claim 1 or 2, wherein the buffer component comprises Tris; preferably, the buffer component comprises Tris and boric acid; Preferably, the buffer component comprises about 500 mM to about 1000 mM Tris and about 500 mM to about 900 mM boric acid.

4. The gel buffer according to any one of claims 1 to 3, wherein the organic additive is an alcohol; preferably, the organic additive is glycerol; preferably, the concentration of the glycerol is about 5% to about 15% v / v.

5. The gel buffer according to any one of claims 1 to 4, wherein the detergent is selected from the group consisting of sodium dodecyl sulfate, sodium tridecyl sulfate, sodium tetradecyl sulfate, sodium pentadecyl sulfate, sodium hexadecyl sulfate, sodium heptadecyl sulfate and sodium octadecyl sulfate; preferably, the detergent is sodium dodecyl sulfate; preferably, the concentration of the sodium dodecyl sulfate is about 0.1% to about 2% w / v.

6. The gel buffer according to any one of claims 1 to 5, wherein the metal chelator is selected from EDTA, DTPA or any combination thereof; preferably, the metal chelator is EDTA; preferably, the concentration of EDTA is about 2 mM to about 15 mM.

7. A gel buffer comprising about 500 mM to about 900 mM Tris, about 500 mM to about 900 mM boric acid, about 12% to about 20% w / v dextran, about 5% to about 15% v / v glycerol, about 0.1% to about 2% w / v SDS, and about 2 mM to about 15 mM EDTA; Alternatively, it comprises about 600 mM to about 900 mM Tris, about 600 mM to about 900 mM boric acid, about 13% to about 20% w / v dextran, about 5% to about 15% v / v glycerol, about 0.2% to about 2% w / v SDS, and about 5 mM to about 15 mM EDTA; Alternatively, it comprises about 600 mM Tris, about 600 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS, and about 5 mM EDTA; Alternatively, it comprises about 850 mM Tris, about 700 mM boric acid, about 15% w / v dextran, about 10% v / v glycerol, about 0.5% w / v SDS and about 5 mM EDTA.

8. Use of the gel buffer according to any one of claims 1 to 7 for CE-SDS detection of protein samples; preferably, the CE-SDS is non-reduced CE-SDS.

9. A method for separating a protein sample by capillary electrophoresis, comprising the following steps: First, add the gel buffer according to any one of claims 1 to 7 into the capillary, inject the protein sample, separate and detect.

10. The method according to claim 9, wherein the capillary has an effective length of about 23 cm to about 30 cm, such as about 24.5 cm or about 28.5 cm, and is a non-coated quartz capillary with an inner diameter of about 50 μm.

11. The method according to claim 9 or 10, wherein the capillary electrophoresis separation voltage is about 10 kV to about 17 kV, such as about 16.5 kV, about 14 kV, about 12 kV or about 10 kV.

12. The method according to claims 9-11, wherein the capillary electrophoresis is detected using a diode array detector with a detection wavelength of about 220 nm.

13. The method according to claims 9-12, further comprising preparing a protein sample.

14. The method according to claims 9-13, further comprising preparing the gel buffer according to any one of claims 1-7.

Citation Information

Patent Citations

  • Capillary gel electrophoresis sample buffer solution containing cysteine

    CN113189184A

  • Methods and compositions for capillary electrophoresis (CE)

    US20040050702A1

  • Separation medium for capillary electrophoresis suppressing electroosmotic flow in bare capillaries and channels

    US20130001084A1

  • Electrophoresis buffer for faster migration, improved resolution and extended shelf-life

    US20130048497A1

  • Method of purity determination by capillary electrophoresis

    US20210025847A1